Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076082 · ClinicalTrials.gov registry record · Phase 4
Vascular Trial Associated Registry Pilot
A Phase 4 study of Peripheral Arterial Disease, sponsored by Corewell Health West.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
- 2
- Study locations
NCT07076082: Recruiting Phase 4 study of Peripheral Arterial Disease, sponsored by Corewell Health West.
NCT07076082 is a Phase 4 study of Peripheral Arterial Disease that is actively recruiting participants, run by Corewell Health West. The registered enrollment target is 350 participants, below the 4,202-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076082, a Phase 4 study of Peripheral Arterial Disease, is actively recruiting participants, sponsored by Corewell Health West.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
Primary Outcome
Patients who undergo PVI that meet inclusion criteria and are offered enrollment.
Conditions Studied
Interventions
- DRUG Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Study Locations (2)
Michigan
- Henry Ford Hospital - Detroit
- Corewell Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 4 |
What NCT07076082 shows while recruiting
NCT07076082 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 4,202-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Clopidogrel (Plavix) Pharmacogenetic Test Reagents is the first listed.
NCT07076082 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07076082 about?
NCT07076082 is a clinical study titled "Vascular Trial Associated Registry Pilot". The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six m...
What is the current status of trial NCT07076082?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2025-10-15. Estimated completion is 2028-10-30.
What conditions does trial NCT07076082 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT07076082?
The interventions under investigation include: Clopidogrel (Plavix) Pharmacogenetic Test Reagents (DRUG).
Who is sponsoring clinical trial NCT07076082?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076082 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07076082's enrollment target sits among peer trials
350 12th of 79 higher than 67 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
ACTIVE NOT RECRUITING · Phase 4
-
The Jetstream G3™ Calcium Study
COMPLETED · Phase 4
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI